Viridian Therapeutics Inc
NASDAQ:VRDN 4:00:00 PM EDT
| Market Cap (Intraday) | 1.07B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $26.36 |
| 50-Day MA | $32.23 |
| 200-Day MA | $23.40 |
Viridian Therapeutics Inc Stock, NASDAQ:VRDN
221 Crescent Street, Suite 401, Waltham, Massachusetts 02453
United States of America
Phone: +1.617.272.4600
Number of Employees: 50
Description
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.